RIP3 antagonizes a TSC2-mediated pro-survival pathway in glioblastoma cell death.

[en] Glioblastomas are the deadliest type of brain cancer and are frequently associated with poor prognosis and a high degree of recurrence despite removal by surgical resection and treatment by chemo- and radio-therapy. Photodynamic therapy (PDT) is a treatment well known to induce mainly necrotic and apoptotic cell death in solid tumors. 5-Aminolevulinic acid (5-ALA)-based PDT was recently shown to sensitize human glioblastoma cells (LN-18) to a RIP3 (Receptor Interacting Protein 3)-dependent cell death which is counter-acted by activation of autophagy. These promising results led us to investigate the pathways involved in cell death and survival mechanisms occurring in glioblastoma following PDT. In the present study, we describe a new TSC2 (Tuberous Sclerosis 2)-dependent survival pathway implicating MK2 (MAPKAPK2) kinase and 14-3-3 proteins which conducts to the activation of a pro-survival autophagy. Moreover, we characterized a new RIP3/TSC2 complex where RIP3 is suggested to promote cell death by targeting TSC2-dependent survival pathway. These results highlight (i) a new role of TSC2 to protect glioblastoma against PDT-induced cell death and (ii) TSC2 and 14-3-3 as new RIP3 partners.

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

Fettweis, Grégory ; Université de Liège > GIGA-R : Virologie - Immunologie

Di Valentin, Emmanuel ; Université de Liège > Département des sciences de la vie > GIGA-R : Virologie et immunologie

L'homme, Laurent

Lassence, Cédric

Dequiedt, Franck ; Université de Liège > Département des Sciences de la vie > GIGA-Research

Fillet, Marianne ; Université de Liège > Département de pharmacie > Analyse des médicaments

Coupienne, Isabelle

Piette, Jacques ; Université de Liège > Département des sciences de la vie > GIGA-R : Virologie et immunologie

Language :

English

Title :

RIP3 antagonizes a TSC2-mediated pro-survival pathway in glioblastoma cell death.

Publication date :

2017

Journal title :

Biochimica et Biophysica Acta

ISSN :

0006-3002

eISSN :

1878-2434

Publisher :

Elsevier, Amsterdam, Netherlands

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 12 April 2017

Statistics

Number of views

191 (12 by ULiège)

Number of downloads

474 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

[1] Omuro, A., DeAngelis, L.M., Glioblastoma and other malignant gliomas: a clinical review. JAMA 310 (2013), 1842-1850.
[2] Stupp, R., Hegi, M.E., Mason, W.P., van den Bent, M.J., Taphoorn, M.J., Janzer, R.C., Ludwin, S.K., Allgeier, A., Fisher, B., Belanger, K., Hau, P., Brandes, A.A., Gijtenbeek, J., Marosi, C., Vecht, C.J., Mokhtari, K., Wesseling, P., Villa, S., Eisenhauer, E., Gorlia, T., Weller, M., Lacombe, D., Cairncross, J.G., Mirimanoff, R.O., R. European Organisation for, T. Treatment of Cancer Brain, G. Radiation Oncology, G. National Cancer Institute of Canada Clinical Trials, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet. Oncol. 10 (2009), 459-466.
[3] Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., Scheithauer, B.W., Kleihues, P., The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114 (2007), 97-109.
[4] Weller, M., van den Bent, M., Hopkins, K., Tonn, J.C., Stupp, R., Falini, A., Cohen-Jonathan-Moyal, E., Frappaz, D., Henriksson, R., Balana, C., Chinot, O., Ram, Z., Reifenberger, G., Soffietti, R., Wick, W., G. European Association for Neuro-Oncology Task Force on Malignant, EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet. Oncol. 15 (2014), e395-e403.
[5] Kanu, O.O., Hughes, B., Di, C., Lin, N., Fu, J., Bigner, D.D., Yan, H., Adamson, C., Glioblastoma multiforme oncogenomics and signaling pathways. Clinical Medicine. Oncology 3 (2009), 39-52.
[6] Bredel, M., Scholtens, D.M., Yadav, A.K., Alvarez, A.A., Renfrow, J.J., Chandler, J.P., Yu, I.L., Carro, M.S., Dai, F., Tagge, M.J., Ferrarese, R., Bredel, C., Phillips, H.S., Lukac, P.J., Robe, P.A., Weyerbrock, A., Vogel, H., Dubner, S., Mobley, B., He, X., Scheck, A.C., Sikic, B.I., Aldape, K.D., Chakravarti, A., Harsh, G.R.t., NFKBIA deletion in glioblastomas. N. Engl. J. Med. 364 (2011), 627-637.
[7] Quirk, B.J., Brandal, G., Donlon, S., Vera, J.C., Mang, T.S., Foy, A.B., Lew, S.M., Girotti, A.W., Jogal, S., LaViolette, P.S., Connelly, J.M., Whelan, H.T., Photodynamic therapy (PDT) for malignant brain tumors—where do we stand?. Photodiagn. Photodyn. Ther. 12 (2015), 530-544.
[8] Albert, I., Hefti, M., Luginbuehl, V., Physiological oxygen concentration alters glioma cell malignancy and responsiveness to photodynamic therapy in vitro. Neurol. Res. 36 (2014), 1001-1010.
[9] Ishizuka, M., Abe, F., Sano, Y., Takahashi, K., Inoue, K., Nakajima, M., Kohda, T., Komatsu, N., Ogura, S., Tanaka, T., Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy. Int. Immunopharmacol. 11 (2011), 358-365.
[10] Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O.D., Zanella, F., Reulen, H.J., Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet. Oncol. 7 (2006), 392-401.
[11] Eljamel, M.S., Goodman, C., Moseley, H., ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. Lasers Med. Sci. 23 (2008), 361-367.
[12] Stylli, S.S., Kaye, A.H., MacGregor, L., Howes, M., Rajendra, P., Photodynamic therapy of high grade glioma - long term survival. Off. J. Clin. Neurosci.: J. Neurosur. Soc. Australas. 12 (2005), 389-398.
[13] Stummer, W., Beck, T., Beyer, W., Mehrkens, J.H., Obermeier, A., Etminan, N., Stepp, H., Tonn, J.C., Baumgartner, R., Herms, J., Kreth, F.W., Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report. J. Neuro-Oncol. 87 (2008), 103-109.
[14] Coupienne, I., Bontems, S., Dewaele, M., Rubio, N., Habraken, Y., Fulda, S., Agostinis, P., Piette, J., NF-kappaB inhibition improves the sensitivity of human glioblastoma cells to 5-aminolevulinic acid-based photodynamic therapy. Biochem. Pharmacol. 81:5 (2010), 606-616.
[15] Huang, J., Manning, B.D., The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412 (2008), 179-190.
[16] Bento, C.F., Ashkenazi, A., Jimenez-Sanchez, M., Rubinsztein, D.C., The Parkinson's disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. Nat. Commun., 7, 2016, 11803.
[17] Garcia-Aguilar, A., Guillen, C., Nellist, M., Bartolome, A., Benito, M., TSC2 N-terminal lysine acetylation status affects to its stability modulating mTORC1 signaling and autophagy. Biochim. Biophys. Acta 1863 (2016), 2658-2667.
[18] Guertin, D.A., Sabatini, D.M., Defining the role of mTOR in cancer. Cancer Cell 12 (2007), 9-22.
[19] Miki, Y., Akimoto, J., Yokoyama, S., Homma, T., Tsutsumi, M., Haraoka, J., Hirano, K., Beppu, M., Photodynamic therapy in combination with talaporfin sodium induces mitochondrial apoptotic cell death accompanied with necrosis in glioma cells. Biol. Pharm. Bull. 36 (2013), 215-221.
[20] Chakrabarti, M., Banik, N.L., Ray, S.K., Photofrin based photodynamic therapy and miR-99a transfection inhibited FGFR3 and PI3K/Akt signaling mechanisms to control growth of human glioblastoma in vitro and in vivo. PLoS One, 8, 2013, e55652.
[21] Coupienne, I., Fettweis, G., Rubio, N., Agostinis, P., Piette, J., 5-ALA-PDT induces RIP3-dependent necrosis in glioblastoma. Photochem. Photobiol. Sci. 10 (2011), 1868-1878.
[22] Miki, Y., Akimoto, J., Moritake, K., Hironaka, C., Fujiwara, Y., Photodynamic therapy using talaporfin sodium induces concentration-dependent programmed necroptosis in human glioblastoma T98G cells. Lasers Med. Sci. 30 (2015), 1739-1745.
[23] Tetard, M.C., Vermandel, M., Leroy, H.A., Leroux, B., Maurage, C.A., Lejeune, J.P., Mordon, S., Reyns, N., Interstitial 5-ALA photodynamic therapy and glioblastoma: preclinical model development and preliminary results. Photodiagn. Photodyn. Ther. 13 (2016), 218-224.
[24] Das, A., McDonald, D.G., Dixon-Mah, Y.N., Jacqmin, D.J., Samant, V.N., Vandergrift, W.A. 3rd, Lindhorst, S.M., Cachia, D., Varma, A.K., Vanek, K.N., Banik, N.L., Jenrette, J.M. 3rd, Raizer, J.J., Giglio, P., Patel, S.J., RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma. Tumour Biol.: J. Int. Soc. Oncodev. Biol. Med., 2015.
[25] Zhang, L., Wang, H., Ding, K., Xu, J., FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells. Toxicol. Lett. 236 (2015), 43-59.
[26] Melo-Lima, S., Celeste Lopes, M., Mollinedo, F., Necroptosis is associated with low procaspase-8 and active RIPK1 and -3 in human glioma cells. Oncoscience 1 (2014), 649-664.
[27] He, S., Wang, L., Miao, L., Wang, T., Du, F., Zhao, L., Wang, X., Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137 (2009), 1100-1111.
[28] Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J., Cantley, L.C., Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10 (2002), 151-162.
[29] Emi, N., Friedmann, T., Yee, J.K., Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. J. Virol. 65 (1991), 1202-1207.
[30] Campeau, E., Ruhl, V.E., Rodier, F., Smith, C.L., Rahmberg, B.L., Fuss, J.O., Campisi, J., Yaswen, P., Cooper, P.K., Kaufman, P.D., A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One, 4, 2009, e6529.
[31] Coupienne, I., Fettweis, G., Piette, J., RIP3 expression induces a death profile change in U2OS osteosarcoma cells after 5-ALA-PDT. Lasers Surg. Med. 43 (2011), 557-564.
[32] Shumway, S.D., Li, Y., Xiong, Y., 14-3-3beta binds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product, tuberin. J. Biol. Chem. 278 (2003), 2089-2092.
[33] Li, Y., Inoki, K., Yeung, R., Guan, K.L., Regulation of TSC2 by 14-3-3 binding. J. Biol. Chem. 277 (2002), 44593-44596.
[34] Yang, X., Cao, W., Zhou, J., Zhang, W., Zhang, X., Lin, W., Fei, Z., Lin, H., Wang, B., 14-3-3zeta positive expression is associated with a poor prognosis in patients with glioblastoma. Neurosurgery 68 (2011), 932-938 (discussion 938).
[35] Martin, M., Potente, M., Janssens, V., Vertommen, D., Twizere, J.C., Rider, M.H., Goris, J., Dimmeler, S., Kettmann, R., Dequiedt, F., Protein phosphatase 2A controls the activity of histone deacetylase 7 during T cell apoptosis and angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 4727-4732.
[36] Nutt, L.K., Buchakjian, M.R., Gan, E., Darbandi, R., Yoon, S.Y., Wu, J.Q., Miyamoto, Y.J., Gibbons, J.A., Andersen, J.L., Freel, C.D., Tang, W., He, C., Kurokawa, M., Wang, Y., Margolis, S.S., Fissore, R.A., Kornbluth, S., Metabolic control of oocyte apoptosis mediated by 14-3-3zeta-regulated dephosphorylation of caspase-2. Dev. Cell 16 (2009), 856-866.
[37] Wang, B., Yang, H., Liu, Y.C., Jelinek, T., Zhang, L., Ruoslahti, E., Fu, H., Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry 38 (1999), 12499-12504.
[38] Li, Y., Inoki, K., Vacratsis, P., Guan, K.L., The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3. J. Biol. Chem. 278 (2003), 13663-13671.
[39] Klotz, L.O., Fritsch, C., Briviba, K., Tsacmacidis, N., Schliess, F., Sies, H., Activation of JNK and p38 but not ERK MAP kinases in human skin cells by 5-aminolevulinate-photodynamic therapy. Cancer Res. 58 (1998), 4297-4300.
[40] Zhang, D.W., Shao, J., Lin, J., Zhang, N., Lu, B.J., Lin, S.C., Dong, M.Q., Han, J., RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325 (2009), 332-336.
[41] Wu, X., Tian, L., Li, J., Zhang, Y., Han, V., Li, Y., Xu, X., Li, H., Chen, X., Chen, J., Jin, W., Xie, Y., Han, J., Zhong, C.Q., Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol. Cell. Proteomics 11 (2012), 1640-1651.
[42] Li, J., McQuade, T., Siemer, A.B., Napetschnig, J., Moriwaki, K., Hsiao, Y.S., Damko, E., Moquin, D., Walz, T., McDermott, A., Chan, F.K., Wu, H., The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 150 (2012), 339-350.
[43] Inoue, H., Kajimoto, Y., Shibata, M.A., Miyoshi, N., Ogawa, N., Miyatake, S., Otsuki, Y., Kuroiwa, T., Massive apoptotic cell death of human glioma cells via a mitochondrial pathway following 5-aminolevulinic acid-mediated photodynamic therapy. J. Neuro-Oncol. 83 (2007), 223-231.
[44] Karmakar, S., Banik, N.L., Patel, S.J., Ray, S.K., 5-Aminolevulinic acid-based photodynamic therapy suppressed survival factors and activated proteases for apoptosis in human glioblastoma U87MG cells. Neurosci. Lett. 415 (2007), 242-247.
[45] Vanden Berghe, T., Linkermann, A., Jouan-Lanhouet, S., Walczak, H., Vandenabeele, P., Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol. 15 (2014), 135-147.
[46] Jouan-Lanhouet, S., Riquet, F., Duprez, L., Vanden Berghe, T., Takahashi, N., Vandenabeele, P., Necroptosis, in vivo detection in experimental disease models. Semin. Cell Dev. Biol. 35 (2014), 2-13.
[47] Xue, L.Y., Chiu, S.M., Oleinick, N.L., Atg7 deficiency increases resistance of MCF-7 human breast cancer cells to photodynamic therapy. Autophagy 6 (2010), 248-255.
[48] Kessel, D., Arroyo, A.S., Apoptotic and autophagic responses to Bcl-2 inhibition and photodamage. Photochem. Photobiol. Sci. 6 (2007), 1290-1295.
[49] Garg, A.D., Maes, H., Romano, E., Agostinis, P., Autophagy, a major adaptation pathway shaping cancer cell death and anticancer immunity responses following photodynamic therapy. Photochem. Photobiol. Sci. 14 (2015), 1410-1424.
[50] Dewaele, M., Martinet, W., Rubio, N., Verfaillie, T., de Witte, P.A., Piette, J., Agostinis, P., Autophagy pathways activated in response to PDT contribute to cell resistance against ROS damage. J. Cell. Mol. Med. 15:6 (2010), 1402-1414.
[51] Broekgaarden, M., Weijer, R., van Gulik, T.M., Hamblin, M.R., Heger, M., Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. Cancer Metastasis Rev. 34 (2015), 643-690.
[52] Tanaka, S., Louis, D.N., Curry, W.T., Batchelor, T.T., Dietrich, J., Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nat. Rev. Clin. Oncol. 10 (2013), 14-26.
[53] Matta, A., Siu, K.W., Ralhan, R., 14-3-3 zeta as novel molecular target for cancer therapy. Expert Opin. Ther. Targets 16 (2012), 515-523.
[54] Harris, K.G., Morosky, S.A., Drummond, C.G., Patel, M., Kim, C., Stolz, D.B., Bergelson, J.M., Cherry, S., Coyne, C.B., RIP3 regulates autophagy and promotes coxsackievirus B3 infection of intestinal epithelial cells. Cell Host Microbe 18 (2015), 221-232.
[55] Matsuzawa, Y., Oshima, S., Nibe, Y., Kobayashi, M., Maeyashiki, C., Nemoto, Y., Nagaishi, T., Okamoto, R., Tsuchiya, K., Nakamura, T., Watanabe, M., RIPK3 regulates p62-LC3 complex formation via the caspase-8-dependent cleavage of p62. Biochem. Biophys. Res. Commun. 456 (2015), 298-304.
[56] Basit, F., Cristofanon, S., Fulda, S., Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. Cell Death Differ. 20 (2013), 1161-1173.